## BMY: Bristol-Myers Squibb Company - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 5.5% in lower entry zone (4.0-10.0%), top quartile (87th pct) cross-sectional ranking. Caution: MRS_5 (-0.2%) diverging from MRS_20, watch for reversal. Outperforming sector by 5.7%. Caution: momentum weakening (-3.2% MRS), overbought RSI (71).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($52.05)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. FDA Approves Bristol-Myers Squibb’s Breyanzi as First-Ever CAR T Therapy for Rare Marginal Zone Lymphoma**
- Source: Yahoo Finance | 20251221T105700 | Bullish | Relevance: 100%
- The FDA has approved Bristol-Myers Squibb’s Breyanzi (lisocabtagene maraleucel) as the first CAR T cell therapy for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have undergone at least two prior systemic therapies. This approval, based on the TRANSCEND FL study, marks Breyanzi's fifth distinct B-cell malignancy approval, demonstrating a 95.5% overall response rate and deep, durable responses. The therapy, administered as a one-time infusion, has an established safety profile for both inpatient and outpatient settings.

**2. FDA Approves Bristol-Myers Squibb’s Breyanzi as First-Ever CAR T Therapy for Rare Marginal Zone Lymphoma**
- Source: Insider Monkey | 20251221T105700 | Bullish | Relevance: 100%
- The FDA has approved Bristol-Myers Squibb’s Breyanzi (lisocabtagene maraleucel) as the first-ever CAR T cell therapy for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have undergone at least two prior systemic therapies. This approval, based on the TRANSCEND FL study, demonstrated an overall response rate of 95.5% with 62.1% achieving a complete response. Breyanzi is now approved for five distinct types of B-cell malignancies.

**3. BofA Upgrades Bristol-Myers Squibb (BMY) Stock to Buy from Neutral**
- Source: Insider Monkey | 20251221T104400 | Bullish | Relevance: 100%
- BofA has upgraded Bristol-Myers Squibb (BMY) stock from "Neutral" to "Buy," increasing its price objective to $61 from $52. This upgrade is based on the company's strong R&D pipeline with upcoming de-risking catalysts and a belief that current stock weakness presents a buying opportunity. Additionally, the U.S. FDA has granted priority review for a new sBLA for Opdivo® in combination with AVD for classical Hodgkin Lymphoma.

**4. Bristol-Myers blood thinner Eliquis offered free to Medicaid as part of U.S. pricing deal**
- Source: Seeking Alpha | 20251220T131035 | Somewhat-Bullish | Relevance: 100%
- The U.S. government has reached drug pricing deals with nine major drugmakers, including Bristol Myers Squibb (BMY). As part of this agreement, Bristol Myers Squibb will provide its blockbuster blood thinner, Eliquis, free of charge to the Medicaid program starting next year. This initiative is a component of broader U.S. efforts to manage drug costs.

**5. Bristol Myers Squibb Company $BMY Shares Sold by Voya Investment Management LLC**
- Source: MarketBeat | 20251221T121853 | Somewhat-Bullish | Relevance: 100%
- Voya Investment Management LLC reduced its stake in Bristol Myers Squibb Company by 9.6% in the third quarter, selling 95,331 shares. Despite this, other institutional investors like Vanguard Group Inc. and Charles Schwab Investment Management Inc. significantly increased their holdings in the biopharmaceutical company. The article also touches upon various news items impacting Bristol Myers Squibb, including agreements with the U.S. government on drug affordability, progress in clinical programs, analyst recommendations, and an announced dividend increase.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $61 | $52 | +17% |
| 2025-12-12 | Morgan Stanley | $37 | $36 | +3% |
| 2025-12-12 | Guggenheim | $62 | $0 | 0% |
| 2025-12-10 | Wells Fargo | $55 | $53 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | up | Buy |
| 2025-12-12 | Morgan Stanley | main | Underweight |
| 2025-12-12 | Guggenheim | up | Buy |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 7 ($0.00M) |
| Sells | 3 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 41.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.5%)
- Blackrock Inc.: 8.6% (+1.9%)
- JPMORGAN CHASE & CO: 8.5% (+65.8%)
- State Street Corpora: 4.7% (+2.0%)
- Charles Schwab Inves: 3.6% (+3.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 5 raises (avg +11%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 2.26 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 34%). Balance sheet: $6.0B free cash flow. Revenue declining -8% YoY, concerning. Analyst sentiment positive (5 raises, avg +11%). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $111.3B |
| Beta | 0.30 |
| 52W Range | $42.52 - $63.33 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.26 |
| Forward P/E | 9.1 |
| Current P/E | 8.4 |
| YoY Growth | -8.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 8.8% to 5.5% (-3.2% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 87th percentile. MRS_5 (-0.2%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 6.2% shows strong absolute momentum above own 20MA. Outperforming sector by 5.7pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 71, risk of mean reversion. Elevated volume (1.6x 20MA), institutional activity likely. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 5.55% (CS: 88) | Strong |
| RSI_14 | 71.0 | Overbought |
| MACD Histogram | 0.18 | Bullish |
| vs SMA20 | 1.062x | Above |
| vs SMA50 | 1.142x | Above |
| vs SMA200 | 1.121x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $54.63
- **Stop Loss:** $52.05 (4.7% risk)
- **Target:** $58.50 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 465
- **Position Value:** $25,402.95
- **Portfolio %:** 25.40%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-05 (Est: $1.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.52 | $1.63 | +7.6% |
| 2025Q2 | $1.10 | $1.46 | +32.6% |
| 2025Q1 | $1.50 | $1.80 | +19.9% |
| 2024Q4 | $1.47 | $1.67 | +13.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*